Science & Enterprise subscription

Follow us on Twitter

  • A company developing protein-like therapies for cancer from synthetic bacteria is being acquired by drug maker Sano… https://t.co/vSjgne2OIz
    about 3 hours ago
  • New post on Science and Enterprise: Synthetic Bio Company Acquired in $2.35B Deal https://t.co/cNWHszuo06 #Science #Business
    about 3 hours ago
  • That's very kind @GRC2001 ... Many thanks. Much appreciated. https://t.co/KNO7c6OnjM
    about 19 hours ago
  • Rice University and the energy company Shell launched a program to sustainably produce carbon derived from splittin… https://t.co/DnO3xbaYe7
    about 22 hours ago
  • New post on Science and Enterprise: Rice Univ, Shell Partner on Sustainable Carbon https://t.co/isa4P4VAve #Science #Business
    about 22 hours ago

Please share Science & Enterprise

Trial to Test Branded vs. Generic Anti-Rejection Drugs

Rita Alloway (University of Cincinnati)

Rita Alloway (University of Cincinnati)

Researchers at University of Cincinnati will lead a clinical trial testing a brand-name drug to reduce rejection of transplants against generic versions. The $2.7 million study, funded by the Food and Drug Administration, includes colleagues from University of Colorado and Cincinnati Children’s Hospital Medical Center.

The trial will test the drug tacrolimus, an immunosuppressant compound marketed under the trade name Prograf by Astrellas Pharma, against two generic versions with liver and kidney transplant patients. Tacrolimus is given to patients after transplants to reduce the activity of the patient’s immune system and lower the risk of rejection.

The drug works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ. As a result the dosage level needs to be carefully calibrated to maximize its effectiveness without causing adverse side effects.

Rita Alloway, a professor of medicine at Cincinnati and principal investigator on the study (pictured left), elaborates saying “Too high exposure to these drugs increases the risk of toxicity, over-immunosuppression, and cancer in patents. Too low exposure may lead to rejection of the organ by the patient’s immune system.”

Because of these concerns, some transplant physicians and their patients are wary of generic versions of the drug, particularly that the quality and therapeutic efficacy of the generics may differ from the branded product. The study will test these concerns in a prospective, blinded, six-way crossover study in stable kidney and liver transplant patients.

The trial will involve two of the most disparate generic versions of tacrolimus, on whether their potency, purity, and concentrations are biologically equivalent to the branded version. “Currently more than 50 percent of transplant patients are dispensed generic tacrolimus,” notes Alloway. “We’re investigating whether even the most disparate generics have the same efficacy in healthy post-transplant patients.”

Read more:

*     *     *

Please share Science & Enterprise ...
error

2 comments to Trial to Test Branded vs. Generic Anti-Rejection Drugs